AZTA Q1 Earnings Call: Revenue Tops Expectations, Margin Progress Amid Macro Headwinds

Life sciences company Azenta (NASDAQ: AZTA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.2% year on year to $143.4 million. Its non-GAAP profit of $0.05 per share was $0.03 below analysts’ consensus estimates.

Is now the time to buy AZTA? Find out in our full research report (it’s free).

StockStory’s Take

Azenta’s first-quarter results reflected continued operational improvements and strategic adjustments in response to a shifting macroeconomic landscape. CEO John Marotta emphasized that growth was led by both the Sample Management Solutions and Multiomics segments, with particular strength in next-generation sequencing and consumables. The company pointed to ongoing cost discipline and productivity initiatives, such as its restructuring efforts and rollout of the Azenta Business System, as contributing factors to year-over-year margin improvement. Management acknowledged that external pressures—such as reduced U.S. academic research funding, tariffs, and geopolitical tensions—required active risk mitigation, including weekly executive reviews and direct customer engagement to understand market dynamics.

Looking forward, Azenta reaffirmed its full-year guidance for organic revenue growth and margin expansion, despite the evolving environment. Marotta noted, “We remain committed to our full-year 2025 guidance of organic revenue growth between 3% and 5%, and adjusted EBITDA margin expansion of 300 basis points.” The company highlighted opportunities to benefit from increased outsourcing by customers facing cost constraints and indicated that its strong balance sheet positions it to pursue targeted acquisitions. Management also plans to update investors more fully at an upcoming Investor Day later this year.

Key Insights from Management’s Remarks

Azenta’s management attributed the company’s performance to a combination of operational restructuring, strategic investment, and proactive customer engagement. The following were the most meaningful drivers of financial results and forward-looking guidance:

• Operational Streamlining: The company completed a global organizational redesign, reducing workforce complexity by nearly 10% and shifting resources toward R&D, sales, and product management. These changes are intended to boost productivity and customer focus.

• Segment Growth Patterns: Sample Management Solutions saw robust growth in consumables, instruments, and storage, while Multiomics benefited from strong next-generation sequencing demand. However, there was softness in Sanger sequencing and gene synthesis, particularly in North America, due to delayed projects and shifting customer priorities.

• Macro and Regulatory Response: Management identified and addressed headwinds from reduced U.S. National Institutes of Health (NIH) funding and new tariffs. Countermeasures were implemented to limit the impact on both revenue and margins, including rapid customer outreach and organizational pivots toward higher-growth segments.

• Digital and Sales Investments: The company increased investment in digital platforms, data analytics, and expanded sales force coverage to capture new business, especially in pharma and biotech. Regional go-to-market models were adopted to better respond to local market conditions, particularly in China and Europe.

• Leadership and Transformation: John Marotta temporarily took direct oversight of Sample Management Solutions following a leadership transition. Additionally, the company appointed Will Simmons as Vice President of the Azenta Business System to drive lean initiatives and continuous improvement through Kaizen workshops and daily management boot camps.

Drivers of Future Performance

Management’s outlook centers on leveraging operational gains and digital investments to drive revenue growth and margin expansion, while remaining vigilant to external risks and market shifts.

• Increased Outsourcing Demand: The company expects continued outsourcing by academic and biopharma customers, driven by cost pressures and funding reductions, to benefit Azenta’s storage and services platforms.

• M&A Pipeline and Cash Position: Azenta’s substantial cash reserves and absence of debt enable it to pursue tuck-in acquisitions that could accelerate growth and enhance margins, particularly as more targets become available in a challenging market.

• Macro and Regulatory Uncertainties: Management remains focused on mitigating risks from tariffs, NIH funding changes, and geopolitical factors. The company’s weekly executive reviews and customer feedback loops are designed to adapt strategy quickly if market conditions worsen.

Top Analyst Questions

• David Saxon (Needham): Asked about the cadence of growth for the remainder of the year and what risks might affect maintaining the low end of guidance. Management stated growth patterns should be similar to prior years, with countermeasures offsetting NIH funding headwinds.

• David Saxon (Needham): Inquired about the Sample Management Solutions leadership transition and whether an internal or external replacement is being considered. CEO John Marotta confirmed he is currently overseeing the segment and emphasized hands-on involvement to drive performance.

• Vijay Kumar (Evercore): Questioned the sustainability of recent free cash flow performance and margin outlook, especially regarding the impact of tariffs. CFO Lawrence Lin explained that improvements stem from working capital execution and that guidance already reflects expected margin impacts from tariffs.

• Paul Knight (KeyBanc): Sought clarity on the salesforce structure and long-term growth expectations for Sample Management Solutions. Marotta discussed regional alignment, investment in sales headcount, and indicated that there is further growth potential beyond current rates.

• Matthew Stanton (Jefferies): Asked about capital deployment priorities, including share repurchases versus M&A. Marotta stated that M&A opportunities are actionable, but all capital allocation levers are on the table, with an emphasis on disciplined returns.

Catalysts in Upcoming Quarters

Going forward, the StockStory team will be watching (1) the pace of margin expansion as operational efficiencies and cost discipline take hold, (2) the impact of recently implemented countermeasures on mitigating macroeconomic headwinds—especially those related to tariffs and research funding, and (3) the company’s ability to execute on M&A opportunities and digital platform investments without disrupting core performance. Updates from the planned Investor Day and ongoing customer feedback initiatives will also be important for assessing strategic progress.

Azenta currently trades at a forward P/E ratio of 37.6×. Should you load up, cash out, or stay put? Find out in our free research report.

Stocks That Trumped Tariffs in 2018

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.